Spondylitis, Ankylosing Clinical Trial
Official title:
Frequency of Pes Planus and Posterior Tibial Tendon Dysfunction in Patients With Ankylosing Spondylitis Ultrasonographic Study
NCT number | NCT04810715 |
Other study ID # | NEAS2021 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 1, 2021 |
Est. completion date | September 1, 2022 |
Verified date | September 2022 |
Source | Afyonkarahisar Health Sciences University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This investigation aims to investigate the frequency of pes planus and posterior tibial tendon dysfunction in patients with ankylosing spondylitis.
Status | Completed |
Enrollment | 100 |
Est. completion date | September 1, 2022 |
Est. primary completion date | September 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 70 Years |
Eligibility | Inclusion Criteria: - Participitans who apply to the rheumatology outpatient clinic between the ages of 20-70 and who have been diagnosed with ankylosing spondylitis according to the Modified Newyork criteria will be included in this study. 1. Ankylosing Spondilitis Exclusion Criteria: 1. Malignity 2. Previous ankle surgery history 3. Muscle disease 4. Neuropsychiatric illnesses 5. Imbalance 6. Visual problems 7. Deafness |
Country | Name | City | State |
---|---|---|---|
Turkey | Afyonkarahisar | Afyonkarahisar |
Lead Sponsor | Collaborator |
---|---|
Afyonkarahisar Health Sciences University |
Turkey,
Arnoldner MA, Gruber M, Syré S, Kristen KH, Trnka HJ, Kainberger F, Bodner G. Imaging of posterior tibial tendon dysfunction--Comparison of high-resolution ultrasound and 3T MRI. Eur J Radiol. 2015 Sep;84(9):1777-81. doi: 10.1016/j.ejrad.2015.05.021. Epub 2015 May 21. — View Citation
Guelfi M, Pantalone A, Mirapeix RM, Vanni D, Usuelli FG, Guelfi M, Salini V. Anatomy, pathophysiology and classification of posterior tibial tendon dysfunction. Eur Rev Med Pharmacol Sci. 2017 Jan;21(1):13-19. Review. — View Citation
Hasler P, Hintermann B, Meier M. Posterior tibial tendon dysfunction and MR imaging in rheumatoid arthritis. Rheumatol Int. 2002 May;22(1):38-40. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | BASDAI includes six questions evaluating five important findings of the disease (Fatigue, hip and spine pain, swelling and pain in peripheral joints, enthesitis, duration and severity of morning stiffness). The pain levels of the patients will be evaluated with a Visual Analog scale (0: I have no pain, 10: I have very severe pain).
Higher scores mean active disease. |
Will be done only once on the first day after inclusion | |
Primary | Bath Ankylosing Spondylitis Functional Index (BASFI) | BASFI; consists of eight questions that evaluate the function of patients with AS and two questions that evaluate their daily life. Higher scores indicate greater limitations. | Will be done only once on the first day after inclusion | |
Primary | Ankylosing Spondylitis Quality of Life Scale (ASQOL) | Ankylosing Spondylitis Quality of Life (ASQoL) scale is a disease-specific assessment parameter designed to measure health-related quality of life. It includes yes or no questions with a total score ranging from 0 to 18. The lower scores represent better quality of life. | Will be done only once on the first day after inclusion | |
Secondary | Functional reach test | Functional reach test: It is the maximum distance that the participants can reach forward in the horizontal plane while maintaining her/his stability on the support surface in the standing position. | Will be done only once on the first day after inclusion | |
Secondary | Timed up and go test (TUG) | The TUG test is a simple evaluative test used to measure functional mobility. It uses the time that participants take to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while turning 180 degrees. During the test, the participant is expected to wear their regular footwear and use any mobility aids that they would normally require.11-20 seconds are within normal limits for frail elderly and disabled patients, and greater than 20 seconds means the worse scores. | Will be done only once on the first day after inclusion | |
Secondary | Berg Balance Scale | The Berg balance scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function and takes approximately 20 minutes to complete. The total score is 56. A score of < 45 indicates participants may be at greater risk of falling. | Will be done only once on the first day after inclusion | |
Secondary | Foot and Ankle Outcome Score (FAOS) | The FAOS is a 42-item questionnaire assessing patient-relevant outcomes in five separate subscales (Pain, other Symptoms, Activities of daily living, Sport and recreation function, foot and ankle-related Quality of life). Scores range from 0 to 100 with a score of 0 indicating the worst possible foot/ankle symptoms and 100 indicating no foot/ankle symptoms. Lower scores mean the worse scores. | Will be done only once on the first day after inclusion | |
Secondary | Ultrasonographic evaluation of the posterior tibial tendon | Posterior tibial tendon evaluation will be evaluated in 2 different locations in the retromalleolar area.Tendon diameter, continuity and fluid presence will be evaluated ultrasonographically. Power Doppler signal levels will be graded on a 4-point semi-quantitative scale (none-grade 0 / minor-grade 1 / middle-grade 2 / severe-grade 3). | Will be done only once on the first day after inclusion | |
Secondary | Static and Dynamic Balance measurment with SportKAT Device. | The SportKAT device used for determining postural oscillation consists of a balance platform and sensors that detect oscillations.There is a screen in front of the participant standing on the platform to provide feedback. During the static balance test, it is asked to keep the 'X' mark seen on the screen constant in the center. During the dynamic balance test, it is asked to to follow the moving cursor. The score range varies between 0 and 6000. The lower the score, the better the balance. | Will be done only once on the first day after inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01208207 -
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
|
Phase 3 | |
Completed |
NCT02509026 -
Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
|
Phase 4 | |
Completed |
NCT02704845 -
Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain
|
N/A | |
Terminated |
NCT01209702 -
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs
|
Phase 3 | |
Terminated |
NCT01209689 -
A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
|
Phase 3 | |
Terminated |
NCT00766402 -
An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)
|
Phase 4 | |
Completed |
NCT00000433 -
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis
|
Phase 2 | |
Completed |
NCT00779935 -
Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)
|
Phase 4 | |
Completed |
NCT00779012 -
A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)
|
Phase 4 | |
Completed |
NCT01863732 -
Extension in AS: Sustainability of Benefits, Safety and Tolerability
|
Phase 3 | |
Recruiting |
NCT05879419 -
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
|
Phase 4 | |
Completed |
NCT01567878 -
Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects
|
N/A | |
Completed |
NCT01188655 -
Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
|
N/A | |
Completed |
NCT00760669 -
An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants
|
Phase 4 | |
Completed |
NCT02159053 -
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT00202865 -
Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)
|
Phase 3 | |
Completed |
NCT02374502 -
Increasing Physical Activity in Ankylosing Spondylitis: a Randomised Controlled Trial
|
N/A | |
Terminated |
NCT00273858 -
Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis
|
N/A | |
Withdrawn |
NCT00298012 -
Methotrexate in the Treatment of Axial Spondyloarthritis
|
Phase 4 | |
Completed |
NCT03880968 -
Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis
|